



EUROPEAN COMMISSION
JOINT RESEARCH CENTRE
Directorate F – Health and Food
Disease Prevention

Annual Declaration of Interests¹ (DoI) form (v3)

European Commission Initiative on Breast Cancer (ECIBC)

Please answer each of the questions below.

If the answer to any of the questions is "Yes"², please complete the corresponding fields, describing the circumstances, as appropriate.

If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the current ECIBC activities.

If you do not disclose relevant activities of interest for the ECIBC, your role may be revised.

¹ According to European Commission's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 11 each member of an expert group has to complete a DoI form

[https://ec.europa.eu/transparency/documents-register/detail?ref=C\(2016\)3301&lang=en](https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en)

² Answering "Yes" to the questions on this form does not automatically limit your participation in the ECIBC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (i.e. any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

Name and Surname:	Prof. Dr. Lebeau, Annette
--------------------------	----------------------------------

Activities	Yes/No	Period (From - To)	Information	Details
1. Do you have current investments³ in a legal entity⁴ with an interest related to breast cancer which either: <ul style="list-style-type: none"> • has a value of more than 10.000 EUR, or • entitle you to a voting right of 5% or more? 	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please provide information about where the investment is placed (Name, Country, Public/Private).	[Please describe the entity and your role.]
2. Have you, within the last five years (January 2018 – December 2022), received remuneration from a legal entity with an interest related to breast cancer? A. Employment	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>			

³ **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (e.g., proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

⁴ **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities	Yes/No	Period (From - To)	Information	Details
B. Consultancy, including advisory activities	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	2018-2022	- Roche Pharma AG, Grenzach-Whylen honorary and travel fees : € 2.100	Consultant and lecture activities (HER2 and PD-L1 testing)
		2018 - 2021	- Novartis Pharma AG, Suisse and Germany honorary and travel fees : € 4.520	Consultant and lecture activities (PIK3CA testing)
		2020-2022	- MSD Sharp & Dohme GmbH, Germany honorary : € 4.300	Consultant and lecture activities (TNBC, PD-L1 testing)
		2020 - present	- Daiichi Sankyo Europe GmbH honorary : € 5.140	Consultant, lecture activities and member of steering committee (HER2 low testing)
		2020 – present	- AstraZeneca, Germany travel fees and honorary : € 13.015,40	Consultant and lecture activities (HER2 low testing)
		2020 - present	- QuIP (Qualitätssicherungs-Initiative Pathologie) GmbH, Germany	Consultant (biomarker analysis)
		2021	- Myriad Genetics SAS, France honorary : € 1.000	Lecture Activities (multigene tests)
2021-2023	- Diaceutics, UK honorary : € 1.650	Steering Committee (investigation on HER2 low testing)		

Activities	Yes/No	Period (From - To)	Information	Details
		12/2020	- Inflection Point Medical Advisors, Spain honorary: € 788	Consultancy (HER2 low testing)
		3/2019	- iMed Institut, Germany travel fees and honorary: € 2.000	Lecture activities (PD-L1 testing)
		9/2021	- If Kongress Management, Germany honorary: € 500	Lecture activities (prognostic and predictive markers)
				<p>I have been asked for single invited presentations on various subjects of breast and surgical pathology on the occasion of scientific meetings. Additionally, I have been asked to perform scientific advisory services by attending single National or European Pathology or Oncology Advisory Board Meetings. None of the lectures or advisory services concern mammography screening. The key aspects are the identification of predictive markers for breast cancer treatment, especially targeted therapies.</p>

Activities	Yes/No	Period (From - To)	Information	Details
<p>3. Have you, within the past five years (January 2018 – December 2022), been involved in research related to breast cancer?</p> <p>A. Have you been an investigator in research studies on breast cancer?</p>	<p>Yes <input checked="" type="checkbox"/></p> <p>No <input type="checkbox"/></p>	<p>2016 - 2020</p> <p>2019 - 2020</p>	<p>« EPI HER2 BC study (ClinicalTrials.gov ID: NCT02666261) »</p> <p>« PaCT Study (PD-L1 Assay Comparison in TNBC)</p>	<p>Participant in « EPI HER2 BC study (ClinicalTrials.gov ID: NCT02666261) », a noninterventional, prospective study of variables influencing HER2-positivity in breast cancer in Germany. The study was published.</p> <p>Participant in « PaCT Study (PD-L1 Assay Comparison in TNBC) », A multicentric, retrospective study on the technical inter-assay and inter-reader comparability of PD-L1 expression in advanced triple-negative breast cancer using clinically relevant IHC assays. The study was published.</p>
<p>B. For the mentioned research studies, did you receive support⁵?</p>	<p>Yes <input checked="" type="checkbox"/></p> <p>No <input type="checkbox"/></p>	<p>2016-2020</p>	<p>Roche Pharma AG, Grenzach-Wyhlen : Allowance for travel expenses, evaluation and documentation (Total ≈11.000€)</p>	<p>1. EPI HER2 BC study (ClinicalTrials.gov ID: NCT02666261)</p> <p>2. PaCT Study (PD-L1 Assay Comparison in TNBC)</p>

⁵ **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).

Activities	Yes/No	Period (From - To)	Information	Details
4. Do you have a membership in national or international organisations⁶, including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies with an interest in breast cancer?	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	2001 – Present	German Cancer Society (Deutsche Krebsgesellschaft e. V.), German Society of Senology (Deutsche Gesellschaft für Senologie e. V.), Berlin	Member of Steering Committee Function as expert: Chair of the Breast Pathology Working Group Function of body: Development of National Guidelines for the Early Detection, Diagnosis and Therapy of Breast Cancer Link to website of body: http://www.senologie.org/publikationen/leitlinien/
		12/2009 – Present	Cooperation alliance mammography (Kooperationsgemeinschaft Mammographie GBR), Berlin	Member of Scientific advisory council Function of expert: Representative for Pathology Function of body: Scientific advice for the Kooperationsgemeinschaft Mammographie Link to website of body: http://www.mammo-programm.de/
		2012 - Present	German Cancer Society (Deutsche Krebsgesellschaft e. V.), Berlin	Member of the Certification Commission “breast cancer centres” Function of expert: Representative of the German Society of Pathology and the Federal Association of German Pathologists Function of body: Compilation of the catalogue of requirements Link to website of body: https://www.krebsgesellschaft.de/deutsche-krebsgesellschaft-wtrl/deutsche-krebsgesellschaft/zertifizierung/erhebungsboegen/organkrebszentren.html

⁶ **Organisation** refers to a governmental, international or non-profit organisation.

Activities	Yes/No	Period (From - To)	Information	Details
		2016 - Present	Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG), Berlin	Member of the Federal Group « Breast surgery » Function of expert: Pathology expert Function of body: Advice on the interpretation of the results of quality assurance and on the further development, revision and maintenance of quality assurance procedures https://iqtig.org/qs-verfahren/mamma/
		2017 – Present	German Society of Pathology (Deutsche Gesellschaft für Pathologie), Berlin	Board Member
		2019 - Present	German Society of Senology (Deutsche Gesellschaft für Senologie e. V.), Berlin	Board Member, Representative for Pathology
		2019 - Present	German Cancer Society (Deutsche Krebsgesellschaft e. V.), Berlin	Member of the Certification Commission “Centres for Familial Breast and Ovarian Cancer” Function of expert: Representative of the German Society of Pathology Function of body: Compilation of the catalogue of requirements Link to website of body: https://www.krebsgesellschaft.de/deutsche-krebsgesellschaft-wtrl/deutsche-krebsgesellschaft/zertifizierung/erhebungsboegen/organkrebszentren.html
		2019 - Present	Federal Association of German Pathologists (Bundesverband Deutscher Pathologen)	Vice President

Activities	Yes/No	Period (From - To)	Information	Details
		2023- Present	International Academy of Pathology (IAP), German Division	Member of the Nomination Committee
5. Did you take part in other activities with interests related to breast cancer?	Yes <input checked="" type="checkbox"/> No <input checked="" type="checkbox"/>	2007 – Present	Reference Centres for Mammography Screening North and Munich	I am appointed reference pathologist in the German mammography screening program performing reference services for two of the five reference centers that are responsible for quality assurance, training and accompanying research. The activity as reference pathologist is honorary and not compensated by a fixed salary.
		2005 – Present	Reference Centre for Mammography Screening Munich in collaboration with the Academy for Training in Morphology e. V. (Akademie für Fortbildung in der Morphologie e. V.)	Course instructor for the training of pathologists in the German mammography screening program. The lectures are paid by the Academy for Training in Morphology e. V. (Akademie für Fortbildung in der Morphologie e. V.)
6. Do you have intellectual property rights (IPR)⁷ related to breast cancer?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please specify the title of the IPR.	Please describe the IPR.

⁷ **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.
European Commission - Joint Research Centre · via E. Fermi, 2749 · I-21027 Ispira (VA), Italy · TP 127
JRC-CANCER-POLICY-SUPPORT@ec.europa.eu

Activities	Yes/No	Period (From - To)	Information	Details
7. Do any of your immediate family members ⁸ have direct interests related to breast cancer that could undermine your independence?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the interest.	Please describe the interest.

⁸ **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

Notes:

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published⁹ before you send the DoI form to the Joint Research Centre (JRC), European Commission.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending a message as soon as possible to: JRC-CANCER-POLICY-SUPPORT@ec.europa.eu.

- I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.
- I agree my DoI form to be publicly available on the JRC Healthcare Quality website, during the European Commission Initiative on Breast Cancer subgroup membership¹⁰.
- I am informed that my personal data are stored, processed and published by the European Commission in accordance with Regulation (EU) 2018/1725¹¹.

Name and Surname: Prof. Dr. Lebeau, Annette

Date: 13.4.2023

Signature:



Place: Herrnburg

⁹ Personal data processing including the Declaration of Interests

<https://ec.europa.eu/dpo-register/detail/DPR-EC-00656>

¹⁰ Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.

¹¹ Protection of individuals with regard to the processing of personal data

<https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725>